The ink is barely dry on the draft Medicare physician fee schedule for 2026, but three cardiology societies blasted the draft for cutting rates for left atrial appendage closure procedures – a move they said needlessly endangers patients.
Boston Scientific Corp. received CE mark certification under the Medical Device Regulation for its Intracept intraosseous nerve ablation system, bringing another treatment option to patients with chronic pain.
Understanding neurological disease requires several things, including a clear view of the connectome, and the U.S. National Institutes of Health may have a solution in the form of a new MRI system that allows the user to examine neural connections at the mesoscopic and microscopic scales.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Ainnova Tech, Alamar Biosciences, Athena Diagnostics, Avant Technologies, Celanese, Community of Nevada Diagnostics, Meliodays, Micron, Pacbio, Quest Diagnostics, Tigermed, T-Neuro, Trilliumbio, U.S. Renal Care, Vexev.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Body Vision, Hardy Diagnostics, Labcorp, Leo Cancer Care, Neu Health.
Radiopharma Clarity Pharmaceuticals Ltd. raised AU$203 million (US$132.22 million) in an institutional placement on Australia’s Securities Exchange to advance its late-stage pipeline of copper-based radiopharmaceuticals.
Trinity Biotech plc recently unveiled CGM+, an AI-native, wearable biosensor that goes beyond traditional continuous glucose monitors and tracks glucose levels, cardiovascular activity and body temperature at the same time. The company believes that as precision medicine becomes central to health care, especially with the collection of real-time data, CGM+ will become a critical enabler of AI-based diagnostics, behavioral coaching and chronic disease management.
RSS
